Gilead Sciences, Inc. $GILD Shares Purchased by Vident Advisory LLC

Key Points

• Vident Advisory LLC increased its stake in Gilead Sciences by 53%, acquiring an additional 13,679 shares to hold a total of 39,507 shares valued at approximately $4.43 million.
• Gilead Sciences reported earnings of $2.01 EPS for the last quarter, exceeding consensus estimates by $0.05, with a quarterly revenue of $7.08 billion which is up 1.4% year-over-year.
• The company recently announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.8%, to be paid on September 29th, affecting shareholders of record on September 15th.

Vident Advisory LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 53.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,507 shares of the biopharmaceutical company's stock after buying an additional 13,679 shares during the quarter. Vident Advisory LLC's holdings in Gilead Sciences were worth $4,427,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $267,000. WPG Advisers LLC bought a new position in shares of Gilead Sciences in the first quarter worth $108,000. Tema Etfs LLC increased its holdings in shares of Gilead Sciences by 25.2% in the first quarter. Tema Etfs LLC now owns 38,622 shares of the biopharmaceutical company's stock worth $4,328,000 after purchasing an additional 7,776 shares during the period. Tri Locum Partners LP purchased a new stake in shares of Gilead Sciences in the first quarter worth $10,023,000. Finally, OMERS ADMINISTRATION Corp boosted its stake in Gilead Sciences by 21.9% during the first quarter. OMERS ADMINISTRATION Corp now owns 84,308 shares of the biopharmaceutical company's stock valued at $9,447,000 after buying an additional 15,125 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 0.2%

GILD stock traded down $0.23 during trading on Thursday, reaching $112.76. The company had a trading volume of 2,177,858 shares, compared to its average volume of 8,091,726. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 52 week low of $77.74 and a 52 week high of $121.83. The business has a 50 day moving average of $113.39 and a 200 day moving average of $109.76. The company has a market cap of $139.92 billion, a P/E ratio of 22.46, a PEG ratio of 0.70 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GILD shares. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares in the company, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,371,330 over the last quarter. Insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.